WallStSmart

Fold Holdings, Inc. Class A Common Stock (FLD)vsNomura Holdings Inc ADR (NMR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nomura Holdings Inc ADR generates 7154517% more annual revenue ($2.17T vs $30.30M). NMR leads profitability with a 16.7% profit margin vs -164.6%. NMR earns a higher WallStSmart Score of 70/100 (B-).

FLD

Hold

38

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 3.3
Piotroski: 3/9Altman Z: -2.33

NMR

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 7.7Quality: 3.5
Piotroski: 4/9Altman Z: 0.53

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FLD2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

EPS GrowthGrowth
1622.0%10/10

Earnings expanding 1622.0% YoY

NMR4 strengths · Avg: 9.0/10
P/E RatioValuation
11.8x10/10

Attractively priced relative to earnings

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

PEG RatioValuation
0.828/10

Growing faster than its price suggests

Revenue GrowthGrowth
27.5%8/10

Revenue surging 27.5% year-over-year

Areas to Watch

FLD4 concerns · Avg: 2.5/10
Market CapQuality
$33.11M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-137.2%2/10

ROE of -137.2% — below average capital efficiency

Revenue GrowthGrowth
-21.1%2/10

Revenue declined 21.1%

NMR4 concerns · Avg: 2.3/10
EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Free Cash FlowQuality
$-1.20T2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.532/10

Distress zone — elevated risk

Debt/EquityHealth
4.671/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : FLD

The strongest argument for FLD centers on Price/Book, EPS Growth.

Bull Case : NMR

The strongest argument for NMR centers on P/E Ratio, Price/Book, PEG Ratio. Profitability is solid with margins at 16.7% and operating margin at 18.7%. Revenue growth of 27.5% demonstrates continued momentum.

Bear Case : FLD

The primary concerns for FLD are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : NMR

The primary concerns for NMR are EPS Growth, Free Cash Flow, Altman Z-Score. Debt-to-equity of 4.67 is elevated, increasing financial risk.

Key Dynamics to Monitor

FLD profiles as a turnaround stock while NMR is a growth play — different risk/reward profiles.

NMR carries more volatility with a beta of 0.61 — expect wider price swings.

NMR is growing revenue faster at 27.5% — sustainability is the question.

FLD generates stronger free cash flow (-7M), providing more financial flexibility.

Bottom Line

NMR scores higher overall (70/100 vs 38/100), backed by strong 16.7% margins and 27.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fold Holdings, Inc. Class A Common Stock

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Fold Holdings, Inc. (FLD) is an innovative biotechnology company dedicated to advancing therapies for severe genetic and rare diseases through its pioneering research initiatives. With a robust product pipeline fortified by proprietary technologies and strategic collaborations, Fold is well-positioned to capitalize on emerging market opportunities. Its commitment to scientific excellence and patient-focused solutions underscores its potential for sustainable growth and value creation, making FLD an attractive investment prospect in the rapidly evolving healthcare sector.

Visit Website →

Nomura Holdings Inc ADR

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Nomura Holdings, Inc. provides various financial services to individuals, corporations, financial institutions, governments, and government agencies worldwide. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?